Biocon Limited

NSE BIOCON.NS

Biocon Limited EPS (Diluted) for the year ending March 31, 2024: USD 0.10

Biocon Limited EPS (Diluted) is USD 0.10 for the year ending March 31, 2024, a 117.44% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Biocon Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.05, a -34.04% change year over year.
  • Biocon Limited EPS (Diluted) for the year ending March 31, 2022 was USD 0.07, a -15.56% change year over year.
  • Biocon Limited EPS (Diluted) for the year ending March 31, 2021 was USD 0.08, a 1.12% change year over year.
  • Biocon Limited EPS (Diluted) for the year ending March 31, 2020 was USD 0.08, a -23.56% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
NSE: BIOCON.NS

Biocon Limited

CEO Mr. Siddharth Mittal BCom, CA, CPA
IPO Date April 7, 2004
Location India
Headquarters 20th KM, Hosur Road
Employees 16,315
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

StockViz Staff

January 16, 2025

Any question? Send us an email